Stay updated on Safety & Immune Response of eOD-GT8 & g28v2 mRNA-1644 Clinical Trial
Sign up to get notified when there's something new on the Safety & Immune Response of eOD-GT8 & g28v2 mRNA-1644 Clinical Trial page.

Latest updates to the Safety & Immune Response of eOD-GT8 & g28v2 mRNA-1644 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new Locations section was added with District of Columbia, Georgia, Texas, and Washington; the District of Columbia, Georgia, Texas, and Washington location entries were removed; the revision updated to v3.3.3.SummaryDifference0.5%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.3.2 is now displayed on the page, replacing the previous Revision: v3.3.1.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision history updated: added Revision v3.3.1 and removed Revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedRemoved the government funding/operating status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedNo meaningful differences in the study record are visible; the page content including Study Overview, Eligibility Criteria, and Study Plan appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check92 days agoChange DetectedUpgrade to v3.2.0 with a prominent operating-status notice and links; v3.1.0 is removed.SummaryDifference3%

Stay in the know with updates to Safety & Immune Response of eOD-GT8 & g28v2 mRNA-1644 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Immune Response of eOD-GT8 & g28v2 mRNA-1644 Clinical Trial page.